Rockefeller Capital Management’s 4D Molecular Therapeutics FDMT Stock Holding History

Rockefeller Capital Management’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$316K	Buy	23,729 +5,875	+33%	+$57.2K	﹤0.01%	2340
2026 Q1	$166K	Sell	17,854 -200	-1%	-$1.74K	﹤0.01%	2602
2025 Q4	$135K	Buy	18,054 +17,929	+14,343%	+$182K	﹤0.01%	2567
2025 Q3	$1.09K	Buy	+125	New	+$747	﹤0.01%	4179
2021 Q4	–	Sell	-1,070	Closed	-$28K	–	3829
2021 Q3	$28K	Sell	1,070 -130	-11%	-$3.71K	﹤0.01%	2428
2021 Q2	$28K	Sell	1,200 -4,735	-80%	-$145K	﹤0.01%	2328
2021 Q1	$257K	Buy	+5,935	New	+$263K	﹤0.01%	1253

Other funds holding FDMT

Jupiter Topco New York $245B AUM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Rockefeller Capital Management's FDMT Position: Q2 2026 in Review

Rockefeller Capital Management increased its 4D Molecular Therapeutics (FDMT) stake by 33% in Q2 2026, buying an estimated $57.2K and bringing the position to 23,729 shares worth $316K. The position accounts for ﹤0.01% of the portfolio, ranked #2340.

Rockefeller Capital Management first reported a position in FDMT in Q1 2021 and has held it in 7 quarters since. 157 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

Rockefeller Capital Management held 23,729 shares of 4D Molecular Therapeutics worth $316K as of Q2 2026.
Rockefeller Capital Management bought 5,875 4D Molecular Therapeutics shares in Q2 2026, an estimated $57.2K.
4D Molecular Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #2340 holding.
Rockefeller Capital Management first reported a position in 4D Molecular Therapeutics in Q1 2021 and has held it in 7 quarters since.
157 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.